Show simple item record

dc.contributor.authorBasri, A.M.
dc.contributor.authorLord, Rianne M.
dc.contributor.authorAllison, Simon J.
dc.contributor.authorRodríguez-Bárzano, A.
dc.contributor.authorLucas, S.J.
dc.contributor.authorJaneway, F.X.
dc.contributor.authorShepherd, H.J.
dc.contributor.authorPask, C.M.
dc.contributor.authorPhillips, Roger M.
dc.contributor.authorMcGowan, P.C.
dc.date.accessioned2017-03-06T15:07:18Z
dc.date.available2017-03-06T15:07:18Z
dc.date.issued2017-05-05
dc.identifier.citationBasri AM, Lord RM, Allison SJ et al (2017) Bis-Picolinamide ruthenium (III) dihalide complexes: dichloride to diiodide exchange generates single trans isomers with high potency and cancer cell selectivity. Chemistry - A European Journal. 23(26): 6341-6356.en_US
dc.identifier.urihttp://hdl.handle.net/10454/11550
dc.descriptionYesen_US
dc.description.abstractA library of new bis-picolinamide ruthenium(III) dihalide complexes of the type RuX2L2 (X = Cl or I and L = picolinamide) have been synthesised and characterised. They exhibit different picolinamide ligand binding modes, whereby one ligand is bound (N,N) and the other bound (N,O). Structural studies reveal a mixture of cis and trans isomers for the RuCl2L2 complexes but upon a halide exchange reaction to RuI2L2, only single trans isomers are present. High cytotoxic activity against human cancer cell lines was observed, with potencies for some complexes similar to or better than cisplatin. Conversion to RuI2L2 substantially increased activity towards cancer cell lines by >12-fold. The RuI2L2 complexes displayed potent activity against the A2780cis (cisplatin-resistant human ovarian cancer) cell line, with >4-fold higher potency than cisplatin. Equitoxic activity was observed against normoxic and hypoxic cancer cells, indicating the potential to eradicate both the hypoxic and aerobic fractions of solid tumours with similar efficiency. Selected complexes were also tested against non-cancer ARPE-19 cells. The RuI2L2 complexes are more potent than the RuCl2L2 analogues, and also more selective towards cancer cells with a selectivity factor >7-fold.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttp://dx.doi.org/10.1002/chem.201605960en_US
dc.rights© 2017 Wiley. This is the peer-reviewed version of the following article: Basri AM, Lord RM, Allison SJ et al (2017) Bis-Picolinamide ruthenium (III) dihalide complexes: dichloride to diiodide exchange generates single trans isomers with high potency and cancer cell selectivity. Chemistry - A European Journal. 23(26): 6341-6356, which has been published in final form at http://dx.doi.org/10.1002/chem.201605960. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.en_US
dc.subjectAnti-cancer; Cytotoxicity; Isomers; Ruthenium(III); Trans-compoundsen_US
dc.titleBis-Picolinamide ruthenium (III) dihalide complexes: dichloride to diiodide exchange generates single trans isomers with high potency and cancer cell selectivityen_US
dc.status.refereedYesen_US
dc.date.Accepted2017-02-17
dc.date.application2017-02-22
dc.typeArticleen_US
dc.type.versionAccepted Manuscripten_US
refterms.dateFOA2018-02-23T00:00:00Z


Item file(s)

Thumbnail
Name:
basri_et_al_2017.pdf
Size:
1.614Mb
Format:
PDF
Description:
Keep suppressed - has older cover ...
Thumbnail
Name:
basri_et_al_2017.pdf
Size:
1.631Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record